Home > Health > View from the Top

Partnerships Are Key to Integrated Solutions

Briza Zorraquin - Grupo CPQ
Development and New Business Manager

STORY INLINE POST

Miriam Bello By Miriam Bello | Senior Journalist and Industry Analyst - Fri, 11/12/2021 - 11:29

share it

Q: What role does the Development and New Business Department play in Grupo CPQ’s business strategy?

A: This department offers integral solutions to meet our clients’ daily needs thanks to our multidisciplinary team, which includes people with different technical and professional training. The department works together with our innovation team, which is in charge of patents and molecules for generic drugs. Grupo CPQ also has a quality management system that handles regulatory matters, technical staff focused on the chemical field and a marketing team that generates proposals for our clients and commercial partners for APIs and functional ingredients.

Q: What is Grupo CPQ’s value proposition and what differentiates it from its competitors?

A: Grupo CPQ does not only rely on client demand but also innovates its own portfolio to offer a wider variety of products. As distributors, we have to be proactive. By integrating APIs and allying with excipient suppliers, we generate a stronger value proposition that strengthens our clients’ portfolios. 

Since 2020 Grupo CPQ has made alliance with Lubrizol Life Science (LLS Health) which is part of the Berkshire Hathaway Group, and has had a presence in Mexico for over than 70 years. Lubrizol is one of the world's largest manufacturers of pharmaceutical grade carbomer and polycarbophilic, currently we are working in an integral strategy with clients in order to accelerate the commercialization of differentiated pharmaceuticals.

Lubrizol's team is dedicated to providing best-in-class polymers and excipients, along with state-of-the-art product design, development and manufacturing services. Its high-performance pharmaceutical´s excipients are used in a wide range of applications including sustained release oral solid dosage forms, transdermal applications, drug delivery device solutions, semi-solid and liquid formulations that help improve absorption and efficacy of drugs, with the goal of creating solutions that improve patient outcomes and quality of life.

Q: The pharmaceutical industry has high quality standards. How does Grupo CPQ verify the quality of its suppliers?

A: Quality is crucial for Grupo CPQ. Recently, we partnered with Lubrizol Life Science Health, which is one of the biggest carbomer and polycarbophil manufacturers globally. Lubrizol has been operating for over 90 years and is part of Berkshire Hathaway, a multinational conglomerate. This alliance gives us security due to the great experience Lubrizol has in manufacturing excipients. The company also helps us offer the best solutions and even propose innovative dosage solutions.

Q: What is Grupo CPQ’s vision for the short and midterm?

A: We will continue offering solutions to our clients that help them put in the market innovative and efficient products that improve the quality of life of patients. Grupo CPQ has been a great partner for the APIs and excipients market. We want our clients to feel sheltered by us as they search for molecules that can make a difference in the pharmaceutical industry.

 

Grupo CPQ has over 35 years of experience in the distribution of APIs and excipients for human pharmaceuticals, animal health and nutrition, nutrition, dosing solutions and care chemicals. 

Photo by:   Grupo CPQ

You May Like

Most popular

Newsletter